Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).

被引：6
|
作者：
Arora, Sukeshi Patel
Tenner, Laura LaNiel
Sarantopoulos, John
Morris, Jay Larry
Longoria, Lisa
Liu, Qianqian
Michalek, Joel
Mahalingam, Devalingam
机构：
[1] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Mays Canc Ctr, Inst Drug Dev, San Antonio, TX USA
[3] Northwestern Univ, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of S-1 plus irinotecan and oxaliplatin for refractory, heavily treated metastatic colorectal cancer
    Kim, S. Y.
    Hong, Y. S.
    Han, H. S.
    Lim, S. B.
    Choi, H. S.
    Jeong, S. Y.
    Jeong, J. Y.
    Hong, C. W.
    Sohn, D. K.
    Jung, K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Efficacy and safety of regorafenib plus biweekly TAS-102 for refractory metastatic colorectal cancer (REGTAS): A multicenter single-arm phase II trial
    Wang, Xiangling
    Li, Zhen
    Sha, Dan
    Ren, Haipeng
    Yi, Cuihua
    Li, Shuguang
    Wang, Peng
    Chu, Yunxia
    Wang, Jian
    Yang, Xiaorong
    Hao, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [44] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
  • [46] Results from the safety lead-in for a phase II study of pembrolizumab in combination with binimetinib and bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).
    Lieu, Christopher Hanyoung
    Davis, Sarah Lindsey
    Leong, Stephen
    Leal, Alexis Diane
    Blatchford, Patrick Jud
    Sandhu, Gurprataap Singh
    Purcell, William T.
    Kim, Sunnie S.
    Van de Voorde, Zoe
    Telles, Rachel
    Martin, Anne
    Cull, Tiffany
    Waring, Meredith
    Reed, Colin
    Lee, Chimmoua
    Siedem, Amanda
    Lee, Matthew R.
    Pitts, Todd
    Eckhardt, S. Gail
    Messersmith, Wells A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [48] Updated phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] UPDATED PHASE II STUDY RESULTS OF CAPECITABINE (X) plus IRINOTECAN (I) plus BEVACIZUMAB (A) AS FIRST-LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Smoljanovic, V
    ANNALS OF ONCOLOGY, 2009, 20 : 76 - 76
  • [50] PROSPECTIVE MULTICENTER PHASE II TRIAL OF 15-MINUTE PANITUMUMAB INFUSION WITH IRINOTECAN IN PATIENTS WITH KRAS WILD-TYPE CHEMO-REFRACTORY METASTATIC COLORECTAL CANCER: THE SHIP TRIAL
    Tetsuya, Hamaguchi
    Kohei, Akiyoshi
    Kenichi, Yoshimura
    Hisateru, Yasui
    Gen, Sakai
    Sotaro, Akatsuka
    Kohei, Ogawa
    Satoshi, Hirai
    Yosuke, Horita
    Yushi, Nagai
    Yasuhiro, Shimada
    ANNALS OF ONCOLOGY, 2014, 25
12345